Sydney, July 15 -- A common anti-nausea drug has been linked to improved survival rates in women with early-stage breast cancer, particularly those with more aggressive triple-negative breast cancer, a study said on Tuesday.
Australian and Norwegian researchers studied 13,811 Norwegian women diagnosed with early-stage breast cancer from 2008 to 2020, all of whom received chemotherapy and anti-nausea medication, according to a statement released by the Melbourne-based Monash University on Tuesday.
Women who took aprepitant during chemotherapy had an 11 percent lower risk of cancer recurrence and a 17 percent lower risk of breast cancer death over 10 years, said the study co-led by the Norwegian Institute of Public Health.
The benefit w...